A detailed history of Gladius Capital Management LP transactions in Innoviva, Inc. stock. As of the latest transaction made, Gladius Capital Management LP holds 1,703 shares of INVA stock, worth $32,186. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,703
Previous 1,703 -0.0%
Holding current value
$32,186
Previous $32,000 -0.0%
% of portfolio
0.02%
Previous 0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

SELL
$16.33 - $20.04 $6,499 - $7,975
-398 Reduced 18.94%
1,703 $32,000
Q2 2024

Jul 18, 2024

SELL
$14.4 - $16.4 $446 - $508
-31 Reduced 1.45%
2,101 $34,000
Q1 2024

May 14, 2024

SELL
$14.56 - $16.78 $4,935 - $5,688
-339 Reduced 13.72%
2,132 $32,000
Q4 2023

Feb 07, 2024

BUY
$12.32 - $16.27 $3,708 - $4,897
301 Added 13.87%
2,471 $39,000
Q3 2023

Dec 18, 2023

SELL
$12.37 - $13.89 $3,030 - $3,403
-245 Reduced 10.14%
2,170 $28,000
Q3 2023

Oct 10, 2023

SELL
$12.37 - $13.89 $3,030 - $3,403
-245 Reduced 10.14%
2,170 $29,000
Q2 2023

Dec 18, 2023

BUY
$11.39 - $13.72 $2,790 - $3,361
245 Added 11.29%
2,415 $30,000
Q2 2023

Aug 08, 2023

SELL
$11.39 - $13.72 $4,909 - $5,913
-431 Reduced 15.14%
2,415 $31,000
Q1 2023

Dec 18, 2023

BUY
$10.73 - $13.6 $7,253 - $9,193
676 Added 31.15%
2,846 $32,000
Q1 2023

May 09, 2023

SELL
$10.73 - $13.6 $697 - $884
-65 Reduced 2.23%
2,846 $33,000
Q4 2022

Dec 18, 2023

BUY
$11.8 - $13.78 $8,743 - $10,210
741 Added 34.15%
2,911 $38,000
Q4 2022

Feb 02, 2023

BUY
$11.8 - $13.78 $1,663 - $1,942
141 Added 5.09%
2,911 $39,000
Q3 2022

Nov 14, 2022

SELL
$11.61 - $15.22 $2,194 - $2,876
-189 Reduced 6.39%
2,770 $33,000
Q2 2022

Aug 10, 2022

BUY
$14.32 - $19.88 $42,372 - $58,824
2,959 New
2,959 $44,000

Others Institutions Holding INVA

About Innoviva, Inc.


  • Ticker INVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 69,706,000
  • Market Cap $1.32B
  • Description
  • Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...
More about INVA
Track This Portfolio

Track Gladius Capital Management LP Portfolio

Follow Gladius Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gladius Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Gladius Capital Management LP with notifications on news.